Alcon: Credit Suisse initiates coverage with 'buy' rating

(CercleFinance.com) - Credit Suisse has begun monitoring the Swiss Alcon share, the eye care division recently spun off by Novartis, adopting a buy ("outperform") rating.


The broker has set a target price of 66 dollars for the share, which is listed in both Zurich and New York, which represents upside potential of 13%.

Analysts first point to Alcon's position as a global leader in its segment. They also point out, that when it was a subsidiary of Novartis, in the last three years, the group made significant investments which are now expected to bear fruit in terms of growth and improvements in margins. This particularly concerns cataracts, retinal surgery and contact lenses.


Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.